Wellcome Genome Campus sets up advisory group for technology and life sciences site

The Wellcome Genome Campus has created a Science & Technology Advisory Group to help guide the scientific and technological direction of its expanding site.

Chaired by Dr Nicole Mather of IBM Consulting, the group includes representatives from Novartis, Genentech, the Wellcome Sanger Institute, EMBL-EBI, the Health Data Research Service and Wellcome, alongside campus leadership.

It has been asked to develop a strategy for what the campus describes as an AI-native district focused on omics, biodata and the use of AI in health and care translation. The group will advise on scientific priorities, emerging opportunities, infrastructure needs and the offer to incoming occupiers.

The move comes as the Wellcome Genome Campus undertakes a major expansion near Cambridge. The site is due to grow from 125 acres to 440 acres, with plans to support a community of 9,000 people or more and attract about 250 companies involved in research, translational development and other commercial activity.

Existing institutions on the campus include the Wellcome Sanger Institute and EMBL’s European Bioinformatics Institute, while the Health Data Research Service is also joining the site. Together, they give the campus an unusual concentration of genomics, biodata and health data organisations within the UK life sciences sector.

Members of the new group include Dr Andy Richards, Dr Avi Spier of Novartis, Professor Ewan Birney of EMBL-EBI, Dr John Marioni of Genentech Research and Early Development, Professor Matt Hurles of the Wellcome Sanger Institute, Dr Melanie Ivarsson of the Health Data Research Service, Neelam Patel and Professor Rachel McKendry of Wellcome.

They are joined by Robert Evans, Chief Executive Officer of Wellcome Genome Campus, Phil Clark, Chair of Wellcome Genome Campus, and Robert Holl of the Wellcome Trust’s investment division.

Expansion plans

The expansion forms part of what the campus describes as one of the UK’s largest recent investments in life sciences and technology infrastructure. The first phase is under way and is expected to be completed by 2028.

Plans for the wider site include new research and translation laboratories, commercial space, incubator and accelerator facilities, homes and community amenities. The project also includes additional data centre computing capacity, energy infrastructure and public realm works.

The expansion reflects a broader push across the Cambridge cluster to add laboratory space and specialised facilities as demand grows from biotechnology, data science and healthcare companies. By bringing research institutes, commercial tenants and national data infrastructure together on one site, the campus is seeking to strengthen its role in that ecosystem.

The arrival of the Health Data Research Service adds another element to that model. It is intended to provide national health data infrastructure, linking the campus’s existing strength in genomics and biological data with clinical and patient outcome information.

Advisory role

The Science & Technology Advisory Group will meet regularly in an advisory capacity. Members will also act as ambassadors for the campus in the UK and overseas.

Its creation signals an effort to shape the scientific identity of the enlarged site before much of the physical build-out is complete. It also brings in senior figures from pharmaceutical companies, research organisations and health data bodies at a time when AI and data-led approaches are becoming more central to biomedical research and clinical development.

Robert Evans outlined the rationale for the new body in a statement on the expansion strategy.

“Our expansion is about creating the right conditions for our science and technology community to thrive. The Science & Technology Advisory Group is helping us to set a clear direction for our future, foster collaboration, commerciality, talent attraction and retention and ensure we continue to grow as a world-class destination,” said Evans.

Dr Mather said the campus had an opportunity to define how biological data and AI are brought together in health research and application.

“The Wellcome Genome Campus is uniquely positioned to shape the future of a key frontier field: how we combine omics, data and AI to transform health and care for people globally. The Science & Technology Advisory Group will create a strategy that builds on the Campus’ pedigree and strengths to grasp the many opportunities now emerging,” said Mather.